Recombinant Zoster Vaccine (Shingrix): a nex gun for Rheumatologist
Herpes Zoster, or as commonly known shingles, is a debilitating painful rash occurring at any age in anyone caused by reactivation of the varicella zoster virus (VZV). The lifetime risk of HZ in the general population is around 30% HZ incidence increases with age and is estimated that 90% of adults...
Main Authors: | D. Marotto, P. Sarzi Puttini, A. Riva |
---|---|
Format: | Article |
Language: | English |
Published: |
Verduci Editore
2022-03-01
|
Series: | Beyond Rheumatology |
Subjects: | |
Online Access: | https://www.beyond-rheumatology.org/wp-content/uploads/sites/10/2022/07/e375.pdf |
Similar Items
-
Position paper of the Italian College of Rheumatologists (CReI) on herpes zoster vaccination
by: D. Marotto, et al.
Published: (2022-12-01) -
The Real-World Study of Immunogenicity and Safety of the Adjuvant Recombinant Vaccine against Varicella Zoster Virus in Patients with Immune-Mediated Inflammatory Diseases Treated with Janus Kinase Inhibitors
by: Ana Esteban-Vazquez, et al.
Published: (2023-10-01) -
A critical appraisal of ‘Shingrix’, a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus
by: Tehmina Bharucha, et al.
Published: (2017-08-01) -
Studies with herpes zoster vaccines in immune compromised patients
by: Myron J. Levin, et al.
Published: (2017-12-01) -
Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
by: Nikolaos Giannelos, et al.
Published: (2023-01-01)